BMS is a Princeton-based pharma leader, revenue-heavy from cancer drugs like Opdivo and Revlimid; in talks with AstraZeneca for a merger that could reshape the sector.
Independent reports that AstraZeneca is in discussions to merge with Bristol Myers Squibb, potentially forming a world-beating pharmaceuticals group. The talks could be among the sector’s largest-ever deals, but sources warn the arrangement may be delayed or fall apart. The UK’s AstraZeneca shares have fallen on the news, while BMS commands a sizable market value in the US.
Pharma licensing assets from China has become the main source for Western drug developers, with Evaluate projecting China-based deals will exceed two-thirds of industry value this year. The shift prompts concerns about hollowing out U.S. biotech capacity while supporters argue it accelerates patient access to new medicines.
The White House has proposed phased tariffs on imported generic medicines, arguing for a U.S.-based manufacturing boost. The plan starts with two years of zero tariffs, followed by 100% and then 200% levies, to spur domestic production. Industry groups warn the move could raise prices for patients while onshoring efforts face structural hurdles. Major manufacturers say margins are thin and shifting production could take years.